相关论文: Explainable histomorphology-based survival predict…
Glioblastoma is one of the most aggressive and common brain tumors, with a median survival of 10-15 months. Predicting Overall Survival (OS) is critical for personalizing treatment strategies and aligning clinical decisions with patient…
Cancer histology reveals disease progression and associated molecular processes, and contains rich phenotypic information that is predictive of outcome. In this paper, we developed a computational approach based on deep learning to predict…
Glioblastoma is the most common and aggressive malignant adult tumor of the central nervous system, with a grim prognosis and heterogeneous morphologic and molecular profiles. Since adopting the current standard-of-care treatment 18 years…
Survival prediction models can potentially be used to guide treatment of glioblastoma patients. However, currently available MR imaging biomarkers holding prognostic information are often challenging to interpret, have difficulties…
Glioblastomas are the most common malignant brain tumors in adults. Approximately 200000 people die each year from Glioblastoma in the world. Glioblastoma patients have a median survival of 12 months with optimal therapy and about 4 months…
Glioblastoma is the most common primary adult brain tumor, with a grim prognosis - median survival of 12-18 months following treatment, and 4 months otherwise. Glioblastoma is widely infiltrative in the cerebral hemispheres and well-defined…
The isocitrate dehydrogenase (IDH) gene mutation is an essential biomarker for the diagnosis and prognosis of glioma. It is promising to better predict glioma genotype by integrating focal tumor image and geometric features with brain…
Glioblastoma (GBM) is an aggressive brain tumor in which IDH mutation status is a key prognostic biomarker, but traditional testing requires invasive biopsies, emphasizing the need for non-invasive approaches. In this multi-center study, we…
Glioma is a common malignant brain tumor with distinct survival among patients. The isocitrate dehydrogenase (IDH) gene mutation provides critical diagnostic and prognostic value for glioma. It is of crucial significance to non-invasively…
Radiomic models have been shown to outperform clinical data for outcome prediction in glioblastoma (GBM). However, clinical implementation is limited by lack of parameters standardization. We aimed to compare nine machine learning…
We propose predictive models that estimate GBM patients' health status of one-year after treatments (Classification task), predict the long-term prognosis of GBM patients at an individual level (Survival task). We used total of 467 GBM…
Glioblastoma Multiforme is a very aggressive type of brain tumor. Due to spatial and temporal intra-tissue inhomogeneity, location and the extent of the cancer tissue, it is difficult to detect and dissect the tumor regions. In this paper,…
Histomorphology is crucial in cancer diagnosis. However, existing whole slide image (WSI) classification methods struggle to effectively incorporate histomorphology information, limiting their ability to capture key pathological features.…
Background: Distinction of IDH mutant and wildtype GBMs is challenging on MRI, since conventional imaging shows considerable overlap. While few studies employed deep-learning in a mixed low/high grade glioma population, a GBM-specific model…
Tumour heterogeneity is increasingly recognized as a major obstacle to therapeutic success across neuro-oncology. Gliomas are characterised by distinct combinations of genetic and epigenetic alterations, resulting in complex interactions…
Precise prognostic modeling of glioblastoma (GBM) under varying treatment interventions is essential for optimizing clinical outcomes. While generative AI has shown promise in simulating GBM evolution, existing methods typically treat…
Currently, there is a noticeable lack of AI in the medical field to support doctors in treating heterogenous brain tumors such as Glioblastoma Multiforme (GBM), the deadliest human cancer in the world with a five-year survival rate of just…
Gliomas are the most common cause of mortality among primary brain tumors. Molecular markers, including Isocitrate Dehydrogenase (IDH) and O[6]-methylguanine-DNA methyltransferase (MGMT) influence treatment responses and prognosis. Deep…
Glioblastoma (GBM) is the most common aggressive, fast-growing brain tumor, with a grim prognosis. Despite clinical diagnostic advancements, there have not been any substantial improvements to patient prognosis. Histopathological assessment…
Glioblastoma is a highly malignant brain tumor with a life expectancy of only 3 to 6 months without treatment. Detecting and predicting its survival and grade accurately are crucial. This study introduces a novel approach using transfer…